BLK
46
2
FCX
44
4
CME
59
3
GT
43
2
ITW
45
2
DG
14
6
ADP
57
2
IPG
43
3
V
70
14
SBUX
29
-2
HP
44
14
BAC
38
3
USB
50
3
PEP
33
4
GM
55
6
DE
49
3
INTC
35
4
GIS
47
13
ICE
53
5
EQR
33
6
BLK
46
2
FCX
44
4
CME
59
3
GT
43
2
ITW
45
2
DG
14
6
ADP
57
2
IPG
43
3
V
70
14
SBUX
29
-2
HP
44
14
BAC
38
3
USB
50
3
PEP
33
4
GM
55
6
DE
49
3
INTC
35
4
GIS
47
13
ICE
53
5
EQR
33
6
Financhill
Back

Akebia Therapeutics 10K Form

Sell
39

AKBA
Akebia Therapeutics

Last Price:
$1.84
Seasonality Move:
7.91%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AKBA News And Ratings

See the #1 stock for the next 7 days that we like better than AKBA

AKBA Financial Statistics

Sales & Book Value

Annual Sales: $194.6M
Cash Flow: $-6.7M
Price / Cash Flow: 0
Annual Sales: $-0.24
Price / Book: 0

Profitability

EPS (TTM): -0.22680
Net Income (TTM): $-46M
Gross Margin: $120.5M
Return on Equity: 0%
Return on Assets: -20.36%

Akebia Therapeutics Earnings Forecast

Key Akebia Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for AKBA is 61.90%.
  • The Selling, General & Administrative Expenses for AKBA have been equal to 51.50% of Gross Profit Margin.
  • The Research & Development expenses have been 32.41% of Revenue.
  • The Interest Expense is -11.62% of Operating Income.
  • The Net Earning history of AKBA is -26.68% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Akebia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AKBA
CUSIP: 00972D
Website: akebia.com

Debt

Debt-to-Equity Ratio: -0.76
Current Ratio: 1.52
Quick Ratio: 1.01

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AKBA Technical Analysis vs Fundamental Analysis

Sell
39
Akebia Therapeutics (AKBA) is a Sell

Is Akebia Therapeutics a Buy or a Sell?